title: [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
abstract: OBJECTIVE
  The objective of this work was to estimate the reliability of MRI after neoadjuvant chemotherapy (NAC) for breast cancer to detect a residual tumour by comparing the tumoral size measured by MRI with the histological size. We also estimated the concordance of diagnosis of complete pathological response between histological examination and MRI.
  
  
  METHODS
  We included all the patients who received a neoadjuvant chemotherapy for breast cancer in the university hospital of Tours from January, 2008 to December 31st, 2012 and in the comprehensive cancer centre of Rennes from January, 2008 till May 31st 201. We considered that the pathological response was complete (pCR) when there was no residual invasive tumour in the mammary surgical specimen.
  
  
  RESULTS
  Two hundred and fifty-one women who received NAC for a non-metastatic breast cancer were included in the study: 103 in Tours and 148 in Rennes. Two women (0.8%) refused breast surgery whatever the type. One hundred and twenty-three (49%) women had a breast conservative surgery. One hundred and fifteen (45.8%) had a mastectomy and 11 (4.4%) had breast conservative surgery followed by mastectomy for positive margins. A complete pathological response was present in 54 cases (21.5%). We did not found any significant difference between characteristics of patients with pCR or not.
  
  
  CONCLUSIONS
  Breast MRI remains the most performing examination to evaluate the initial tumoral size and the residual tumour after NAC, but does not add any value at mid or at the end of treatment for the patients to whom a mastectomy is decided at presentation. The correlation between the breast MRI and the histology size is not perfect, but at the moment, MRI stills of the most performing examination to predict the pCR.
authors.affiliation: Département de gynécologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Faculté de médecine François-Rabelais, 10, boulevard Tonnellé, 37044 Tours, France.
authors.forename: C
authors.initials: C
authors.lastname: Brisson
authors.affiliation: Département de gynécologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Faculté de médecine François-Rabelais, 10, boulevard Tonnellé, 37044 Tours, France.
authors.forename: C
authors.initials: C
authors.lastname: Diguisto
authors.affiliation: Département de radiologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
authors.forename: A
authors.initials: A
authors.lastname: Vildé
authors.affiliation: Département de gynécologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Faculté de médecine François-Rabelais, 10, boulevard Tonnellé, 37044 Tours, France; Unité Inserm 1069, 10, boulevard Tonnellé, 37044 Tours, France.
authors.forename: G
authors.initials: G
authors.lastname: Body
authors.affiliation: Département de pathologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
authors.forename: F
authors.initials: F
authors.lastname: Arbion
authors.affiliation: Département de gynécologie, hôpital Sud, CRCL CRLCC Eugène-Marquis, centre hospitalier régional universitaire de Rennes, 35000 Rennes, France.
authors.forename: J
authors.initials: J
authors.lastname: Leveque
authors.affiliation: Département de gynécologie, hôpital Bretonneau, centre hospitalier régional universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Faculté de médecine François-Rabelais, 10, boulevard Tonnellé, 37044 Tours, France; Unité Inserm 1069, 10, boulevard Tonnellé, 37044 Tours, France. Electronic address: l.ouldamer@chu-tours.fr.
authors.forename: L
authors.initials: L
authors.lastname: Ouldamer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001940:Breast / Q000000981:diagnostic imaging* / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018365:Neoplasm, Residual; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D015203:Reproducibility of Results; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
keywords: Breast cancer; Cancer du sein; Chemotherapy; Chimiothérapie; Imagerie par résonance magnétique; Magnetic resonance imaging; Neodjuvant; Néoadjuvant; Pathological complete response; Réponse histologique complète